China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
SACRAMENTO, Calif., May 19, 2016 -- The Orange County Register published an opinion piece today by Bridget Hood, a lupus survivor and Lupus L.A. board member and support group facilitator. May is Lupus Awareness Month, dedicated to raising awareness and promoting medical innovation to find treatments or a cure for this debilitating autoimmune disease. Hood has been a continued voice for medical innovation and research.
In the opinion piece, "A time to recommit to the fight against lupus," Hood makes the case that policy makers must do everything in their power to create policies that protect patients and ensure these life-saving medications are available to all who need them.
"The right kinds of public policy can offer hope for those of us who are fighting for new treatments and a cure. Policy makers in Sacramento and Washington D.C. play an important role in helping patients continue their fight. It is vital that we continue to move forward with medical innovation, and not make any kind of policy decisions that would intentionally or unintentionally slow that progress down."
View the full column at The Orange County Register: http://www.ocregister.com/articles/lupus-716357-patients-disease.html
Learn more about the value of medical innovation at www.CALifeSciences.org/Innovation.
|
|||||
About California Life Sciences Association (CLSA)
California Life Sciences Association (CLSA) is the leading voice driving innovation for California's life sciences sector. CLSA works closely with industry, government, academia and other stakeholders to shape public policy, drive business solutions and grow California's life sciences innovation ecosystem. CLSA serves over 750 biotechnology, pharmaceutical, medical device, and diagnostics companies, research universities and institutes, investors and service providers. CLSA was founded in 2015 when the Bay Area Bioscience Association (BayBio) and the California Healthcare Institute (CHI) merged to create the state's most influential life sciences advocacy and business leadership organization. Visit CLSA at www.califesciences.org, and follow us on Twitter @CALifeSciences, Facebook, Instagram, LinkedIn and YouTube.
Media Contact:
Will Zasadny
Associate Director, Communications
[email protected]
CONTACT: Will Zasadny
Associate Director, Communications
[email protected]
